Description

APOQUEL 16 MG

Indications

APOQUEL (oclacitinib) 16 mg is primarily indicated for the control of pruritus associated with allergic dermatitis and the treatment of atopic dermatitis in dogs. It is designed for use in dogs aged 12 months and older. The medication provides rapid relief from itching and inflammation, improving the quality of life for pets suffering from these conditions.

Mechanism of Action

APOQUEL functions as a Janus kinase (JAK) inhibitor. It selectively inhibits JAK1 and JAK3 enzymes, which play a crucial role in the signaling pathways of various cytokines and growth factors involved in the inflammatory response. By blocking these pathways, APOQUEL effectively reduces the production of pro-inflammatory cytokines, thereby alleviating symptoms of itching and inflammation associated with allergic and atopic dermatitis.

Pharmacological Properties

APOQUEL is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1 to 2 hours. The bioavailability of the drug is approximately 75%. It is metabolized primarily in the liver and is excreted through both urine and feces. The elimination half-life of APOQUEL is around 4 to 6 hours, which allows for its twice-daily dosing regimen in the initial treatment phase. The drug has a low potential for drug-drug interactions due to its specific metabolic pathway.

Contraindications

APOQUEL should not be administered to dogs with a known hypersensitivity to oclacitinib or any of its components. It is contraindicated in dogs that are pregnant, lactating, or under 12 months of age. Additionally, dogs with a history of neoplasia or serious infections should be evaluated carefully before initiating treatment, as the immunosuppressive effects of the drug may exacerbate these conditions.

Side Effects

While APOQUEL is generally well tolerated, some dogs may experience side effects. The most common adverse reactions include vomiting, diarrhea, lethargy, and decreased appetite. In rare cases, more serious side effects such as skin infections, urinary tract infections, or other opportunistic infections may occur due to the immunosuppressive effects of the drug. It is essential for pet owners to monitor their dogs closely and report any unusual symptoms to their veterinarian.

Dosage and Administration

The recommended dosage of APOQUEL for dogs is based on their weight. For dogs weighing less than 15 lbs (6.8 kg), the dosage is 3.6 mg given twice daily for up to 14 days, followed by a maintenance dose of 3.6 mg once daily. For dogs weighing between 15 to 30 lbs (6.8 to 13.6 kg), the initial dosage is 5.4 mg twice daily for up to 14 days, followed by a maintenance dose of 5.4 mg once daily. For dogs weighing between 30 to 60 lbs (13.6 to 27.2 kg), the initial dosage is 16 mg twice daily for up to 14 days, followed by a maintenance dose of 16 mg once daily. For dogs over 60 lbs (27.2 kg), the dosage is 16 mg once daily. It is crucial to follow the veterinarian’s instructions regarding dosage and duration of treatment.

Interactions

APOQUEL has a low potential for drug interactions due to its specific metabolic pathway. However, caution should be exercised when used concurrently with other immunosuppressive agents, corticosteroids, or non-steroidal anti-inflammatory drugs (NSAIDs), as these may increase the risk of adverse effects. It is essential to inform the veterinarian of all medications and supplements the dog is currently receiving to ensure safe and effective treatment.

Precautions

Before starting treatment with APOQUEL, a thorough veterinary examination should be conducted to rule out any underlying conditions that may contraindicate its use. Regular monitoring of the dog’s health is recommended during treatment, especially for those with a history of infections or neoplasia. Pet owners should be educated about the signs of potential side effects and the importance of adhering to the prescribed dosage and treatment regimen.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of APOQUEL in managing pruritus associated with allergic dermatitis and atopic dermatitis in dogs. In one pivotal study, dogs treated with APOQUEL showed a significant reduction in itching and improvement in skin condition compared to placebo-treated dogs. The onset of action was rapid, with many dogs experiencing relief within 24 hours of the first dose. Long-term studies have also indicated that APOQUEL can be safely administered for extended periods, with most dogs maintaining a good quality of life throughout treatment.

Conclusion

APOQUEL 16 mg is a valuable therapeutic option for the management of pruritus associated with allergic and atopic dermatitis in dogs. Its unique mechanism of action as a JAK inhibitor allows for rapid relief of symptoms while minimizing the risk of significant side effects. As with any medication, it is essential for pet owners to work closely with their veterinarians to ensure the safe and effective use of APOQUEL, tailoring treatment plans to meet the individual needs of their pets.